• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    WallachBeth Capital Announces Closing of Bullfrog AI Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million

    10/21/24 1:00:00 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRG alert in real time by email

    JERSEY CITY, N.J., Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has closed its previously announced definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00. The warrants will have an exercise price of $2.00 per share, are initially exercisable on the date that is six months from the date of issuance and will expire five years from such initial exercise date.

    The gross proceeds from the offering are expected to be approximately $3.13 million, excluding any proceeds that may be received upon exercise of the warrants and before deducting the placement agent's fees and other offering expenses payable by the Company.

    WallachBeth Capital, LLC acted as sole placement agent for the registered direct offering and private placement. Sheppard, Mullin, Richter & Hampton LLP acted as counsel to the placement agent.

    The shares of common stock, the pre-funded warrants and the shares of common stock underlying the pre-funded warrants (but not the common warrants or the shares of common stock underlying the common warrants) will be issued in a registered direct offering pursuant to an effective shelf registration statement on Form S-3 (File No. 333-281341) previously filed with the U.S. Securities and Exchange Commission ("SEC"), under the Securities Act of 1933, as amended (the "Securities Act"), and declared effective by the SEC on August 21, 2024. The common warrants to be issued in the concurrent private placement and the shares issuable upon exercise of such common warrants were offered pursuant to an exemption from the registration requirements of the Securities Act under Section 4(a)(2) thereof and Regulation D promulgated thereunder and have not been registered under the Securities Act or applicable state securities laws. The offering of the shares of common stock and pre-funded warrants is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.  A prospectus supplement describing the terms of the proposed registered direct offering will be filed with the SEC and available on the SEC's website located at http://www.sec.gov. Electronic copies of the prospectus supplements may be obtained, when available, from WallachBeth Capital, LLC, via email at [email protected], by calling +1 (646) 237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About WallachBeth Capital LLC:

    WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, private transactions and ATM's.

    Forward-Looking Statements

    This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company's offering of securities and the expected closing of the offering. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions and include the intended use of proceeds. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to risks and uncertainties included under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q filed by the Company and other reports filed with the SEC from time to time. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-closing-of-bullfrog-ai-registered-direct-offering-and-concurrent-private-placement-for-aggregate-gross-proceeds-of-3-13-million-302282072.html

    SOURCE WallachBeth Capital LLC

    Get the next $BFRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What financial transaction has Bullfrog AI Holdings, Inc. recently completed?

      Bullfrog AI Holdings, Inc. closed a definitive agreement for a registered direct offering and private placement worth approximately $3.13 million.

    • How many shares and warrants were involved in Bullfrog AI's recent offering?

      The offering includes the sale of 1,565,000 shares of common stock at a price of $2.00 each and warrants to purchase an additional 1,565,000 shares at the same price.

    • Who facilitated the capital raising for Bullfrog AI's securities?

      WallachBeth Capital, LLC acted as the sole placement agent for the offering.

    • What are the key terms associated with the warrants issued in Bullfrog AI's offering?

      The warrants will be exercisable six months from the date of issuance and will expire five years later, at an exercise price of $2.00 per share.

    • What are the estimated gross proceeds from Bullfrog AI's offering?

      The gross proceeds are approximately $3.13 million, excluding potential future proceeds from the exercise of the warrants.

    Recent Analyst Ratings for
    $BFRG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BFRG
    SEC Filings

    View All

    SEC Form 424B5 filed by Bullfrog AI Holdings Inc.

    424B5 - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    4/1/26 4:42:42 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    4/1/26 2:56:09 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    3/30/26 5:56:59 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder

    Commercial agreement serves as high-profile third party validation of BullFrog AI's proprietary capabilities Agreement utilizes BullFrog AI's end-to-end analytical AI platform to accelerate drug discovery and development program  GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today announced a commercial agreement with a top 5 global pharmaceutical company in 2025 by revenue ("Customer"), to apply the Company's proprietary bfLEAP® platform to identify and prioritize

    3/30/26 7:30:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine

    GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, today unveiled bfARENAS™, a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design, bolstering its end-to-end AI intelligence workflow. The Company will host a webinar in partnership with Xtalks Life Sciences on bfARENAS™ on March 27, 2026 at 11 a.m. ET. Organizations across biotech, pharma, and clinical research operate in high-uncertainty environments where timelines are lon

    3/25/26 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog to Host Webinar on New Precision AI Capability

    GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, will host a webinar in partnership with Xtalks Life Sciences, "Turning AI Recommendations into Clear, Defensible Decisions", about BullFrog AI's new precision AI capability on Friday, March 27, 2026 at 11 a.m. ET. The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision support layer on top of existing platforms bfPREP™ and bfLEAP®. Unlike traditional portfolio tools t

    3/11/26 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hanson Jason David

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    9/29/25 8:16:41 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Enright William

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    9/29/25 8:14:44 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Elsey R Don

    4 - BullFrog AI Holdings, Inc. (0001829247) (Issuer)

    9/29/25 8:12:13 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Leadership Updates

    Live Leadership Updates

    View All

    BullFrog AI Issues Letter to Stockholders

    GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa

    12/27/24 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Announces Appointment of Chief Financial Officer

    GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer. "Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and

    12/17/24 4:30:00 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni

    GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientific research and technology-driven drug discovery. Dr. Baldoni's career includes 29 years in R&D at GSK, where he served as Senior Vice President of Platform and Technology Sciences, lea

    10/15/24 7:30:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    Financials

    Live finance-specific insights

    View All

    BullFrog AI and GreenPower Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / April 26, 2024 / RedChip Companies will air interviews with BullFrog AI Holdings, Inc. (NASDAQ:BFRG) and GreenPower Motor Company Inc. (NASDAQ:GP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BullFrog AI: https://www.redchip.com/assets/access/bfrg_accessGreenPower: https://www.redchip.com/assets/access/gp_accessIn an exclusive interview, Vin Singh, CEO of BullFrog AI, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corporate u

    4/26/24 9:00:00 AM ET
    $BFRG
    $GP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    ASP Isotopes and Bullfrog AI Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / October 27, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG)(NASDAQ:BFRGW) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessBullfrog AI: https://www.redchip.com/assets/access/bfrg_accessPaul Mann, CEO, of ASP Isotopes appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. ASP Isoto

    10/27/23 9:00:00 AM ET
    $ASPI
    $BFRG
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedChip Launches 'Small Stocks, Big Money' Podcast

    New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list

    8/2/23 12:45:00 PM ET
    $BFRG
    $LTRN
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology